Biomedicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, Douglas, Queensland, Australia; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia.
Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia; WHO Collaborating Centre for Reference and Research on Influenza at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Vaccine. 2020 Feb 28;38(10):2368-2377. doi: 10.1016/j.vaccine.2020.01.066. Epub 2020 Feb 5.
Seasonal influenza vaccination with a standard trivalent influenza vaccine (TIV) induces a modest, and cross-reactive, Fc functional antibody response in older adults. Recent improvements to influenza vaccines include a quadrivalent influenza vaccine (QIV) and a TIV adjuvanted with the squalene-based oil-in-water emulsion MF59.
Pre- and post-vaccination serum samples from older adults vaccinated with QIV (n = 27) and adjuvanted TIV (n = 44) were studied using hemagglutination inhibition (HAI) assays and dimeric Fc-gamma receptor IIIa binding ELISAs, as a surrogate of antibody-dependent cellular cytotoxicity (ADCC).
We found that the unadjuvanted QIV elicited a stronger HAI response against the H1N1 vaccine virus than the adjuvanted TIV. Post-vaccination levels of HA-specific ADCC antibodies were similar for older adults vaccinated with QIV and adjuvanted TIV. The ADCC response to influenza vaccination was largely determined by pre-vaccination or baseline levels of these antibodies, with older adults with low baseline levels of ADCC activity demonstrating greater post-vaccination rises.
In this cohort of community-dwelling older adults, the QIV was at least as good as the adjuvanted TIV in the induction of ADCC and HAI responses. Further studies on how these antibody responses translate to efficacy in preventing influenza infections are warranted.
在老年人中，接种标准三价流感疫苗（TIV）会引起适度的、交叉反应的 Fc 功能抗体反应。最近对流感疫苗的改进包括四价流感疫苗（QIV）和用角鲨烯为基础的水包油乳剂 MF59 佐剂的 TIV。
用血凝抑制（HAI）试验和二聚体 Fc-γ受体 IIIa 结合 ELISA 研究了接种 QIV（n=27）和佐剂 TIV（n=44）的老年人接种疫苗前后的血清样本，作为抗体依赖的细胞毒性（ADCC）的替代物。
我们发现，未佐剂的 QIV 对 H1N1 疫苗病毒的 HAI 反应比佐剂 TIV 更强。接种 QIV 和佐剂 TIV 的老年人的 HA 特异性 ADCC 抗体水平相似。流感疫苗接种的 ADCC 反应在很大程度上取决于这些抗体的接种前或基线水平，基线 ADCC 活性水平低的老年人接种后的上升幅度更大。
在这组社区居住的老年人中，QIV 在诱导 ADCC 和 HAI 反应方面至少与佐剂 TIV 一样好。进一步研究这些抗体反应如何转化为预防流感感染的疗效是有必要的。
